Is excisional biopsy warranted after a diagnosis of flat epitelial atypia (FEA) at vacuum-assisted biopsy?
0
Citation
0
Reference
12
Related Paper
Abstract:
Poster: ECR 2015 / C-0632 / Is excisional biopsy warranted after a diagnosis of flat epitelial atypia (FEA) at vacuum-assisted biopsy? by: P. Merino Rasillo , P. Alonso Bartolome, E. Ortega Garcia, S. M. Sanchez Gomez, E. Torres Diez, A. Vega Bolivar; Santander/ESKeywords:
Atypia
Cite
Poster: ECR 2013 / C-0385 / Papillary lesions of the breast diagnosed by core needle biopsy: clinicoradiological features and management of 65 cases with surgical follow-up by: C. Medina Vila 1, I. C. Duran Palacios2, M. Noriega Collado3, L. Salazar Garcia3, M. J. Martin Marcos3; 126001/ES, 2LOGRONO, LA/ES, 3Logrono/ES
Core biopsy
Cite
Citations (0)
Abstract BACKGROUND: Flat epithelial atypia (FEA) is a recently described breast lesion that may coexist with cancer or atypical ductal hyperplasia (ADH). Currently, there is no consensus on whether to surgically excise FEA diagnosed by core needle biopsy. Our aim was to perform a systematic review and meta-analysis of pertinent studies to determine the frequency of upgrade to cancer or ADH at surgical excision of "pure" FEA (no other high risk lesion on core biopsy). METHODS: A retrospective search was performed using MEDLINE, Embase, Scopus and Web of Science databases from 1/2003- 4/2014 to capture studies on core biopsy diagnosed FEA followed by surgical excision. Search terms were: FEA, flat epithelial atypia, DIN1A, columnar cell, breast diseases, core needle biopsy. Inclusion criteria were: 1) manuscript with original data on FEA diagnosed on core needle biopsy, 2) data included outcome of cancer at surgical excision, 3) English Language. RESULTS: Of 224 articles, 30 met inclusion criteria. StudyTotal Pure FEA cases%N excisedN upgraded to cancer% upgradedLim, 2006862.55120Kunju 20071485.712325Martel 20076338.124938Piubello, 20093360.62000Chivukula, 20093989.735514Senneta,20094187.83600Hayes, 200981008113Davashian, 20091210012217Tamasino, 20095444.424313Noske, 20104369.83027Lee, 20101546.77114Ingegnoli, 20101883.315320Noel, 20106232.32000Flegg, 2010NANA5240Sohn, 20113666.72428Lavoue, 20116010060813Rakha, 20112410024521Soloranzo,20113384.828414Verschuur-Maes, 20116934.824938Peres, 201212879.71021010Uzoaru, 201214565.69533Bianchi, 2012190100190189Biggar, 2012511005136Yamaguchi, 20121747.18113Polom, 20122010020210Khoumais, 201310490.4941011Villa, 201314285.212176Becker, 201330378.9239104Ceugnart, 20136382.55236Uzan, 2013351003500 Across 1420 patients with pure FEA in 30 studies, observed proportions with upgrade to cancer varied from 0-40% with a pooled estimate of 11% (95% CI: 8-15%) using a random effects model. Test for heterogeneity was statistically significant (p < 0.0001, I2 statistic=58%). After excluding 7 studies with <50% (or unreported %) of all FEA cases excised, heterogeneity decreased (p=0.07, I2=32%) and the pooled estimate of cancer upgrade was 9% (95% CI: 7-12%). For upgrade to ADH, 693 subjects with pure FEA were analyzed from 21 studies. The percent upgraded to ADH ranged from 0-60% with significant heterogeneity (p < 0.0001, I2 = 64%). Excluding 4 studies with <50% of FEA cases excised did not improve heterogeneity (p < 0.0001 and I2 = 66%). The random effects model pooled estimate of upgrade to ADH was 16% (95% CI: 11-23%) for the 21 studies and 17% (95% CI: 12-25%) for the subset of 17 studies. CONCLUSION: The pooled upgrade rate of FEA to cancer was 9-11% and upgrade to ADH was 16-17%. For patients with FEA on core needle biopsy, surgical excision should be strongly considered. Citation Format: Anatoliy V Rudin, Hoskin L Tanya, Ann M Farrell, Amy C Degnim. Flat epithelial atypia on core biopsy and upgrade to cancer: A systematic review and meta-analysis [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-06.
Atypia
Cite
Citations (0)
Flat Epithelia Atypia (FEA) is a proliferative lesion of the breast where cells demonstrate columnar change and cytologic atypia. This lesion has been identified as distinct from the classic atypical hyperplasias (AH). While many patients undergo excisional biopsy, management of FEA identified on core needle biopsy (CNB) is controversial, and the rate of associated ductal carcinoma in situ (DCIS) or invasive cancer is not well defined. The aim of this study was to determine the upstage rate of FEA diagnosed by CNB. We identified patients from a prospectively maintained data base who had FEA diagnosed by CNB from 01/2010 to 07/2015. Patient variables collected included age at presentation, imaging findings, pathologic findings following surgical excision, and subsequent development of breast cancer. Of 132 patients, 62 (n = 62/132, 47.0%) patients had FEA associated with DCIS and invasive ductal carcinoma (IDC) on CNB and were excluded from analysis. Of the remaining 70 patients, median age was 52 (range 31-84) years. Thirty-two (45.7%) patients had FEA plus AH, 4 (5.7%) patients had FEA plus lobular carcinoma in situ (LCIS), and 34 (48.6%) patients had FEA alone or with another non-pathologic finding (pure FEA). Two (6.3%) patients with FEA plus AH had DCIS or IDC on subsequent excisional biopsy. Of the 34 patients with pure FEA who underwent excisional biopsy, only one (2.9%) was found to have IDC. Twenty-two (64.7%) patients with pure FEA who underwent excisional biopsy presented with calcifications on mammography. None of these patients had cancer on excisional biopsy, and 10 (45.5%) patients had AH (3 ADH, 3 ALH, and 4 both ALH and ADH). Twelve (n = 12/34, 35.3%) patients with pure FEA underwent CNB for a mass or asymmetry noted on imaging. Of these 12 patients, 9 (75.0%) had benign findings on excisional biopsy, two (16.7%) patients had AH, and one (8.3%) patient had IDC. Median follow-up was 4.6 years (IQR 3.1-6.5 years). Three (4.3%) patients subsequently developed IDC, two of which were in the contralateral breast. FEA is often found in combination with ADH and ALH as well as carcinoma on CNB. In our study, pure FEA was upstaged to cancer in only 2.9% of patients. Mammographic findings unlikely predict upstaging to malignancy. These findings suggest that excisional biopsy may not be warranted in patients with pure FEA and could be managed with close imaging surveillance.
Atypia
Lobular carcinoma
Carcinoma in situ
Cite
Citations (14)
Sampling error
Atypia
Value (mathematics)
Core biopsy
Cite
Citations (4)
Poster: ECR 2012 / C-0241 / Managing risk lesions of the breast diagnosed with stereotactic vacuum-assisted breast Correlation with surgical biopsy. by: S. Plaza Loma, Y. Rodriguez de Diego, E. Villacastin Ruiz, R. Ramos Martin, R. Pintado Garrido, I. Anacabe Goyogana; Valladolid/ES
Breast biopsy
Stereotactic biopsy
Cite
Citations (0)
PURPOSE: To compare histologic findings of atypical ductal hyperplasia (ADH) at 14-gauge, directional, vacuum-assisted breast biopsy (hereafter, vacuum-assisted biopsy) and at 14-gauge, automated, large-core breast biopsy (hereafter, large-core biopsy) with findings at histologic examination after surgical biopsy. MATERIALS AND METHODS: Nonpalpable breast lesions were diagnosed as ADH at histologic examination after vacuum-assisted biopsy in 88 lesions in seven institutions and after large-core biopsy in 55 previously reported lesions. Histologic findings at subsequent surgical biopsy were compared for the presence of carcinoma. RESULTS: On the basis of histologic findings of carcinoma at surgical biopsy, the diagnosis of ADH was not correct in 26 (48%) of 54 lesions sampled at large-core biopsy and in 13 (18%) of 74 lesions sampled at vacuum-assisted biopsy (Fisher exact test, P < .0004). More tissue specimens were obtained at vacuum-assisted biopsy (mean, 15.8 specimens) than at large-core biopsy (mean, 9.7 specimens). Individual specimens were twice as large at vacuum-assisted biopsy (mean, 34 mg) as at large-core biopsy (mean, 17 mg) (previously reported). CONCLUSION: ADH was diagnosed 2.7 times more reliably at vacuum-assisted biopsy than at large-core biopsy (with no increase in complications) with most of the improvement as a result of acquisition of more than 10 specimens per lesion, but carcinoma was sufficiently underestimated with both methods to necessitate surgical biopsy.
Breast biopsy
Core biopsy
Cite
Citations (252)
FOREWORD: Flat Epithelial Atypia (FEA) is one of the high-risk breast lesions (HRL), with low degree cytological atypia. Its management (surgery v/s intensive follow-up) after percutaneous procedures diagnosis is still controversial.
OBJECTIVES: The goal of the study was to determine the frequency of pure FEA on stereotactic biopsies (SB) and the histological underestimation (HU) after it s surgical excision.
MATERIALS AND METHODS: Retrospective review of 537 SB performed in 485 women (30-72 yr), old (mean 49.9 yr. ) in Clinica Alemana de Santiago between June 2009 and April 2012. To assess HU, were excluded cases with other high-risk lesions (atypical ductal hyperplasia, lobular neoplasia, radial scar, mucocelelike lesions, papillary lesions) and ductal carcinoma in situ (DCIS) or invasive cancer in the SB histology. Also excluded pure FEA cases that didn t undergo surgical excision.
RESULTS: Of all biopsied focuses, 217 (40.4%) were high risk lesions, and FEA was found on 175 of them (80.6%). Pure FEA was diagnosed in 38 cases (7% total; 17.5% HRL); of such 20 (52.6%) underwent surgical excision. (i) No cases with DCIS or invasive cancer (UH 0%) was found in the definitive histology.(ii) 40 % of FEA cases were associated to atypical ductal hyperplasia and 20% to lobular neoplasia. From the 18 patients did not undergo surgery, 10 (55.5%) continued to be monitored, with a mean follow-up of 14 month. Only one case showed progression of residual micro-calcifications, and was suggested to biopsy again.
CONCLUSION: FEA is a diagnosis to by familiar with, especially because of lack of enough scientific evidence that allows to create handling patterns after is diagnosed by percutaneal procedures. Our results suggest that surgery may not be needed in all cases, especially when FEA appears as a collateral finding, or unique focus, microfocus or when a full extraction of micro-calcifications during biopsy is achieved.
Atypia
Histology
Cite
Citations (0)
Background
Nonpalpable mammographic abnormalities are frequently evaluated by means of a stereotactic core needle biopsy. This technique is a very sensitive indicator of invasive cancer, but is less reliable to discriminate between ductal carcinoma in situ and atypical ductal hyperplasia (ADH). The objective of this study was to determine the correlation of the 11-gauge vacuum-assisted core needle biopsy to open biopsy when a diagnosis of ADH is obtained.Hypothesis
The use of 11-gauge vacuum-assisted stereotactic core needle biopsy does not conclusively diagnose ADH.Design
Retrospective analysis.Setting
University-affiliated teaching hospital.Patients
Mammographic findings were evaluated with an 11-gauge vacuum-assisted stereotactic core biopsy in 1750 patients. Seventy-seven patients were diagnosed as having ADH; of these, 65 underwent excisional biopsy.Main Outcome Measures
Pathological upstaging rate.Results
Of the 65 patients who underwent excisional breast biopsy, 11 (17%) had their condition upstaged to a breast cancer diagnosis. These patients had presented at a later age than those who retained a benign diagnosis after excisional biopsy. The number of cores taken did not correlate with diagnostic accuracy.Conclusions
Of the 65 patients who underwent open biopsy for ADH in this series, only 83% had an accurate diagnosis. A diagnosis of ADH by stereotactic core needle biopsy should be followed by an open excisional biopsy.Stereotactic biopsy
Atypical Hyperplasia
Open biopsy
Breast biopsy
Cite
Citations (94)
To determine whether flat epithelial atypia (FEA) found in isolation on large core vacuum-assisted biopsy (CNB) requires surgical excision. After Institutional Review Board approval, pathology reports of all patients who underwent CNB from January 1, 2005 to December 31, 2010 were reviewed. All patients with reports of isolated FEA without other atypia or in situ or invasive carcinoma were identified. Patient age, history, target on imaging, biopsy modality, and residual target post CNB noted. Histology of CNB's (blinded to surgical outcome) and subsequent surgical excisions were reviewed by a dedicated breast pathologist. Only cases with confirmed isolated FEA on review were used for data analysis. Of 2,556 CNB's performed over 6 years, 37 (1.4%) had isolated FEA confirmed on review, comprising our study population. Thirty (81%) had biopsy for calcifications on mammography and 7 (19%) for mass or non-mass like enhancement on magnetic resonance imaging. There were no US guided CNBs that met our inclusion criteria. 29 (78.4%) underwent surgical excision, 6 (16.2%) had imaging follow-up, and 2 (5.4%) were lost to follow-up. Of the 29 with surgery, 2 (6.9%) had "upgrade" to low-grade in situ carcinoma (1 ductal and 1 pleomorphic lobular), 5 (17.2%) had "change in diagnosis" to other atypia (ADH/ALH), 15 (51.7%) had additional FEA and 7 (24.2%) had benign tissue without atypia. Both "upgraded" cases had residual microcalcifications on imaging following CNB. There were no upgrades to invasive cancers. In our study, none of 29 with isolated FEA on CNB had invasive cancer on surgical excision. If there are residual microcalcifications or residual lesion after a CNB that shows isolated FEA, excision is warranted, due to the possibility of other atypia (ADH/ALH [17.2%] or DCIS [5.4%]). If there are no residual microcalcifications following CNB, imaging follow-up as an alternative to surgery may be a reasonable option.
Atypia
Lobular carcinoma
Cite
Citations (45)
To assess the impact on the final outcome at surgery of flat epithelial atypia (FEA) when found concomitantly with lobular neoplasia (LN) in biopsy specimens compared with pure biopsy-proven FEA.The approval from the institutional review board of the CHUM (Centre Hospitalier Universitaire de Montréal) was obtained. A retrospective review of our database between 2009 and 2013 identified 81 females (mean age 54 years, range 38-90 years) with 81 FEA biopsy-proven lesions. These were pure or associated with LN only in 59/81 (73%) and 22/81 (27%) cases, respectively. Overall, 57/81 (70%) patients underwent surgery and 24/81 (30%) patients underwent mammographic surveillance with a mean follow-up of 36 months.FEA presented more often as microcalcifications in 68/81 (84%) patients and were mostly amorphous in 49/68 (72%). After excluding radio pathologically discordant cases, pure FEA proved to be malignant at surgery in 1/41 (2%; 95% confidence interval 0.06-12.9). There was no statistically significant difference in the upgrade to malignancy whether FEA lesions were pure or associated to LN at biopsy (p = 0.4245); however, when paired in biopsy specimens, these lesions were more frequently associated with atypical ductal hyperplasia (ADH) at surgery than with pure FEA (p = 0.012).Our results show a 2% upgrade rate to malignancy of pure FEA lesions. When FEA is found in association with LN at biopsy, surgical excision yields more frequently ADH than pure FEA thus warranting close surveillance or even surgical excision. Advances in knowledge: The association of LN with FEA at biopsy was more frequently associated with ADH at surgery than with pure FEA. If a biopsy-proven FEA lesion is deemed concordant with the imaging finding, when paired with LN at biopsy, careful surveillance or even surgical excision is suggested.
Atypia
Breast biopsy
Nuclear atypia
Cite
Citations (8)